SCHEMBL14575487

SCHEMBL14575487

Oc1ccc(Oc2ccc(O)c(I)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ESR1 P03372 1/20 0.58
ESR2 Q92731 1/20 0.58
LTA4H P09960 3/20 0.50
NR1H2 P55055 1/20 0.50
BAX Q07812 1/20 0.50
THRB P10828 5/20 0.49
THRA P10827 4/20 0.49
PCNA P12004 4/20 0.49
POLB P06746 2/20 0.49
HIF1A Q16665 2/20 0.49
LMNA P02545 2/20 0.49
ABCB11 O95342 1/20 0.49
CYP1A2 P05177 1/20 0.49
PGR P06401 1/20 0.49
CHRM2 P08172 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADORA3 P0DMS8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14575001 0.91 THRB (0.54) MEN1KMT2AESR1ESR2THRB
SCHEMBL2784791 0.86 LTA4H (0.54) MEN1KMT2ALTA4HNR1H2BAX
SCHEMBL14616574 0.83 THRB (0.49) MEN1KMT2ATHRBTHRAPCNA
SCHEMBL3957209 0.82 MEN1 (0.70) MEN1KMT2AESR1ESR2LTA4H
SCHEMBL14616573 0.81 MEN1 (0.61) MEN1KMT2AESR1ESR2LTA4H
SCHEMBL24407712 0.80 THRB (0.54) MEN1KMT2ATHRBTHRAPCNA
SCHEMBL24407715 0.78 THRB (0.52) MEN1KMT2AESR2THRBTHRA
SCHEMBL13886595 0.77 TAAR1 (0.56) MEN1KMT2ATHRBTHRAPCNA
SCHEMBL7811939 0.76 ESR2 (1.00) MEN1KMT2AESR1ESR2LTA4H
SCHEMBL3175106 0.76 ESR2 (1.00) MEN1KMT2AESR1ESR2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220146930-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-05-12 US disclosed
US-10220100-B2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery LATHAM KEITH R (US) 2019-03-05 US disclosed
US-20180369395-A9 Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery LATHAM KEITH R (US) 2018-12-27 US disclosed
US-20180117164-A1 Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery LATHAM KEITH R (US) 2018-05-03 US disclosed
US-9144613-B2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery LATHAM KEITH R (US) 2015-09-29 US disclosed
US-9125946-B2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery LATHAM KEITH R (US) 2015-09-08 US disclosed
EP-2755939-A2 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY Latham, Keith, R. (US) 2014-07-23 EP disclosed
US-20140134105-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LATHAM KEITH R (US) 2014-05-15 US disclosed
US-20140135397-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LATHAM KEITH R (US) 2014-05-15 US disclosed
US-8673269-B2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery LATHAM, KEITH 2014-03-18 US disclosed
US-20130022549-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LATHAM, KEITH 2013-01-24 US disclosed
US-20130017163-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY IPE, INC. 2013-01-17 US disclosed
US-20130018026-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY IPE, INC. 2013-01-17 US disclosed
US-20130017163-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY IPE, INC. 2013-01-17 US disclosed
US-20130017163-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY IPE, INC. 2013-01-17 US disclosed
WO-2013010102-A2 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LATHAM KEITH R (US) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018026-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY COMT, GPX4, GPX1 MEN1 4765/4885KMT2A 3407/4885ESR1 193/4885
US-20140134105-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LPO, AHR, TDO2 MEN1 4844/4885KMT2A 3314/4885ESR1 901/4885
US-20180369395-A9 Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery COMT, GPX4, GPX1 MEN1 4765/4885KMT2A 3407/4885ESR1 193/4885
US-10220100-B2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery COMT, GPX4, GPX1 MEN1 4765/4885KMT2A 3407/4885ESR1 193/4885
US-20180117164-A1 Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery COMT, GPX4, GPX1 MEN1 4765/4885KMT2A 3407/4885ESR1 193/4885
US-20140135397-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY COMT, GPX4, GPX1 MEN1 4765/4885KMT2A 3407/4885ESR1 193/4885
US-20220146930-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN RER1, FGFR1, NHERF1 MEN1 2209/4885KMT2A 1914/4885ESR1 662/4885
US-20130022549-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY LPO, AHR, TDO2 MEN1 4844/4885KMT2A 3314/4885ESR1 901/4885
US-20130017163-A1 HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY TYR, PRDX5, PPARG MEN1 4824/4885KMT2A 3626/4885ESR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.